Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0649

+0.6%

Nov 13 3:42 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: NTTG who wrote (12312)	8/13/2013 11:59:22 AM
From: Mimbari	of 13111

FOOL! The drug that failed had an inadequate way of vectoring. The problem with antigen pre-tuned vaccines is that they are made to target one specific antigen. And it never responded to enough of the tumor. PII study of theirs showed such a low response rate one might assume it was background noise in the data. PIII showed it was. But they did write lots of papers and did things the way you would have. But like you they never saw the bigger picture because like you they were nose to the data set near sighted. It should have never went to PIII. You like them would follow your data and publishing fetish and push a company into a hole.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next